AIM
ATRA icon

Aigen Investment Management’s Atara Biotherapeutics ATRA Stock Holding History

Aigen Investment Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-419
Closed -$206K – 617
2020
Q4 		$206K Sell
419
-2,240
-84% -$1.03M 0.03% 673
2020
Q3 		$861K Buy
+2,659
New +$906K 0.11% 293

Other funds holding ATRA

Baupost Group
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Maverick Capital
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Credit Suisse
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Aigen Investment Management's ATRA Position: Q1 2021 in Review

Aigen Investment Management sold out of Atara Biotherapeutics (ATRA) in Q1 2021, closing a stake of 419 shares — an estimated $206K sold.

Aigen Investment Management first reported a position in ATRA in Q3 2020 and held it in 2 quarters. The position peaked at $861K in Q3 2020. 151 funds tracked by Wall St. Rank hold ATRA as of Q1 2021.

  • Aigen Investment Management reported no remaining Atara Biotherapeutics position as of Q1 2021 after selling out during the quarter.
  • Aigen Investment Management sold 419 Atara Biotherapeutics shares in Q1 2021, an estimated $206K.
  • Aigen Investment Management first reported a position in Atara Biotherapeutics in Q3 2020 and held it in 2 quarters.
  • Aigen Investment Management's Atara Biotherapeutics position peaked at $861K in Q3 2020.
  • 151 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2021.

Based on Aigen Investment Management's 13F filing for Q1 2021, filed 11 May 2021.